Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
Stevens KN, Wang X, Fredericksen Z, Pankratz VS, Greene MH, Andrulis IL, Thomassen M, Caligo M; Swedish Breast Cancer Study, Sweden (SWE-BRCA); Nathanson KL, Jakubowska A, Osorio A, Hamann U, Godwin AK, Stoppa-Lyonnet D, Southey M, Buys SS, Singer CF, Hansen TV, Arason A, Offit K, Piedmonte M, Montagna M, Imyanitov E, Tihomirova L, Sucheston L, Beattie M; HEreditary Breast and Ovarian Cancer Group Netherlands (HEBON); German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC); Neuhausen SL; CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella (CONSIT Team); Szabo CI; kConFab; Simard J, Spurdle AB, Healey S, Chen X, Rebbeck TR, Easton DF, Chenevix-Trench G, Antoniou AC, Couch FJ.
Stevens KN, et al. Among authors: pankratz vs.
Breast Cancer Res Treat. 2012 Nov;136(1):295-302. doi: 10.1007/s10549-012-2255-6. Epub 2012 Sep 26.
Breast Cancer Res Treat. 2012.
PMID: 23011509
Free PMC article.